Latest News

A selection of recent news and views from Catapult Ventures follows...

Infex Therapeutics receives MHRA approval to initiate Phase 1 study for RESP-X programme

MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022 Alderley Park, Cheshire, U.K – Infex Therapeutics, a leader in critical-priority infectious diseases, is pleased to announce it has received approval from the...

Maxwellia appoints Ian Adamson as Strategic Advisor

Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches – a process which involves identifying and converting suitable prescription only medicines into versions people can choose to...

Catapult Ventures records 3.3x return from exit of Panthera Biopartners

2 April 2022 - Manchester, UK.  The GM&C Life Sciences Fund, managed by Catapult Ventures, has announced a 3.3x cash return (115.6% IRR), from its exit of Panthera Biopartners Ltd. The exit comes as part of a £10m further funding p...

Medicine switching expert Maxwellia continues to drive shift to self-care with two more pharmacy products in the launch pipeline

MANCHESTER, England, April 22, 2022 /PRNewswire/ -- Following the reclassification of the daily progestogen-only pill earlier this year, Maxwellia made history by launching Lovima® (desogestrel 75mcg) one of the first oral...

Oxford BioTherapeutics grants third exclusive license to Boehringer Ingelheim

  Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target OXFORD, England and SAN JOSE, Calif., April 13, 2022 /...

From our portfolio

Bitrobius Genetics

Biotechnology

Bitrobius is a start-up biotechnology company developing a synthetic gene transfer technology for...

viewview our portfolio

Our Team

Dr Gareth King

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
Enderby
Leicester
LE19 4XT

Tel: 0116 238 8200

email